With one of the largest footprints in biotech, Cowen sets the standard for thought leadership and impactful strategic advice.

Research capabilities for
Biotech sector

Cowen’s biotech team has one of the largest research footprints in the space, covering companies pioneering the treatment of diseases. Our analysts’ work has been validated in third-party polls, such as Institutional Investor’s All-America Research Team, the Greenwich Associates poll, and Starmine. In addition to company-specific research, publications such as Biotechnology Quarterly have become legend among investors. Similarly, our Ahead Of The Curve™ reports are at the center of conversation.

Numerous biotechnology reports make use of Cowen’s extensive network of clinicians to help our analysts guage market potential for therapeutics options. We have also created proprietary programs as needed to support our analysts’ research.

Our annual Health Care Conference remains one of Wall Street’s most highly regarded, and is the epicenter of discussion for corporate executives, institutional investors, venture capitalists, and health care professionals. We also host annually the Cowen Therapeutics Conference that provides an ideal forum for objective, first-hand views on both marketed and emerging therapeutics.

Learn more about our research expertise


General Contact

Robert Fagin
Head of Research
D 646 562 1310

Stephen E. Reilly
Co-director of Research
D 617 946 3901

Lisa Thomas
Associate Director of Research
D 646 562 1388

Investment Banking capabilities for
Biotech sector

Cowen is a leading bank for high quality financings and financial advisory for life sciences companies. The biotech investment banking team combines the global resources and full service product capabilities of a leading financial institution with the focus and commitment of a specialty investment banking firm.

We have proven track record of providing impactful strategic advice and a superior ability to execute debt and equity transactions as well mergers and acquisitions. We understand our clients’ unique challenges and opportunities and deliver the entire organization to help clients’ achieve their goals.

Learn more about our investment banking expertise

Latest Transactions

  • Dermira, Inc. will use the proceeds of the $125.0 million Term Loan to support the ongoing commercial launch of QBREXZA, fund the development of lebrikizumab (Phase 2b ongoing), and for general corporate purposes.
  • Rocket Pharmaceuticals intends to use the net proceeds from this offering, together with its existing cash and cash equivalents, to fund the continued development of the pipeline of gene therapies for rare diseases, enhancements to in-house manufacturing efforts, potential in-license, acquisition or investment in complementary businesses or products, and intends to use the remainder for general working capital and administrative purposes.
  • Acadia intends to use the net proceeds of this offering to fund ongoing commercialization efforts for NUPLAZID, ongoing and new clinical trials and development efforts for pimavanserin and trofinetide, and for general corporate purposes, including working capital.


General Contact

George Milstein
Head of Health Care
D 415 646 7394